Common mucocutanoeous toxicities from novel cancer targeted therapy
Keywords:
Mucocutaneous toxicity, Targeted therapy, Malignant tumourAbstract
The mucocutanoeus toxicities were commonly found in patients treated with chemotherapy or radiation therapy. The targeted therapy aims to destroy the malignant cells directly at the molecular level of abnormal cellular changes and preserve normal cellular organs. Erlotinib, Cetuximab and Imatinib mesylate are the example of available drugs used nowadays as standard treatment in colorectal carcinoma, non-small cell lung cancer and head and neck cancer. The common toxicities from this type of treatment uniquely related to skin and mucous membrane.
References
Pegram MD, Pietras R, Bajamonde A, et al: Targeted therapy: Wave of the future. J Clin Oncol 2005; 23: 1776-81.
Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents 2004; 4: 139-48.
Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 3815-25.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associ¬ated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1,425-33.
Matheis P, Socinski MA, Burkhart C, Warren S, Thomas NE. Treatment of gefitinib-associated folliculitis. J Am Acad Dermatol 2006; 55: 710-3.
Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab-induced acne. Dermatology 2005; 211: 330-3.
Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153:849-51.
Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005; 141: 1173-4.
Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: Clinical expe¬rience and management. Clin Lung Cancer 2003; 4: 366-9.
Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: Case 1. Paro¬nychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 4646-8.
Monti M, Mancini LL, Ferrari B, Rahal D, Santoro A. Compli¬cations of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 2003; 21: 4651-3.
Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 2006;154:191-2.
Montagut C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 2005; 23: 5273-5.
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hema¬tologic and cytogenetic responses in patients with acceler¬ated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-37.
Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J Med 2002; 347: 472-480.
Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holy¬oake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003; 120: 911-3.
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-6.
Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Steven-Johnson syndrome after treatment with STI571: A case report. Br J Haematol 2002;117:620-2.
Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Derma-tology 2001; 203: 57-9.
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(1):16–24.
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontin¬uation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromo-some-positive leukemias. N Engl J Med 2006; 354: 2531-41.
Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassman B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2009 Thai Journal of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
